GoHealthcare Practice Solutions · Regulatory-Validated Authority Guide

Spinal Cord Stimulator Prior Authorization Requirements: Medicare, WISeR, CPT 63650 & 63655

An operational guide to SCS trial and permanent implantation authorization, Medicare HOPD prior authorization, WISeR, Medicare Advantage, commercial payer criteria, documentation, coding alignment, denials, and audit readiness.

Pinky Maniri, MSc · CEO & Founder, GoHealthcare Practice Solutions · Regulatory validation: August 19, 2026

Direct answer

Spinal cord stimulation has two clinical decision stages - trial and permanent implantation - but it does not have one universal two-authorization pathway. The authorization transaction depends on payer, beneficiary type, CPT code, site of service, state, and applicable Medicare contractor policy. For Original Medicare, CPT 63650 is subject to the nationwide Hospital Outpatient Department prior-authorization program when furnished in that setting; in six WISeR states, CPT 63655 is currently subject to the WISeR prior-authorization or pre-payment-review model. Medicare Advantage and commercial plans use their own authorization processes, but Medicare Advantage medical-necessity criteria remain subject to federal Medicare coverage rules. ^{S1 S2 S3 S4 S5 S8}

SCS prior authorization at a glance

CPT 63650 in a hospital outpatient department: currently subject to the nationwide Original Medicare Hospital OPD prior-authorization program.
CPT 63655 in a WISeR state: currently falls within the WISeR SCS pathway for applicable Original Medicare cases in Arizona, New Jersey, Ohio, Oklahoma, Texas, and Washington.
Trial versus permanent implant: these are separate clinical stages, but they are not always separate prior-authorization transactions.
Medicare Advantage and commercial plans: verify the current plan-specific authorization workflow, medical-necessity criteria, site, provider, code, units, and effective policy version.

Why spinal cord stimulator authorization deserves its own operating discipline

Related GoHealthcare resource: Explore GoHealthcare’s Neuromodulation specialty page and the detailed Prior Authorization for SCS, PNS & DRG guide for the broader neuromodulation operating framework.

Spinal cord stimulation concentrates clinical, financial, and compliance risk in a relatively small number of high-value cases. The authorization file must support medical necessity, the planned technology and procedure, the site of service, the responsible billing entity, and the eventual claim. A weakness in any one of those domains can delay care, create a preventable denial, or increase post-payment review exposure.

For leadership, SCS authorization should be managed as a revenue-integrity and clinical-access function rather than as a generic clerical queue. The operational objective is not merely to “get an authorization.” It is to create a defensible evidence file, route the case through the correct payer program, preserve the authorization or Unique Tracking Number (UTN) through scheduling and billing, and ensure that the service actually performed is consistent with the approved or affirmed request.

GoHealthcare Analysis: A dedicated SCS workflow is justified because the service line combines staged clinical decision-making, variable payer criteria, device-intensive economics, multiple billing entities, and meaningful audit exposure. CMS currently maintains an approved Recovery Audit Contractor topic for SCS medical necessity and documentation requirements, reinforcing that authorization is only one layer of defensibility. ^S9

Two clinical gates - but not always two authorization transactions

The cleanest way to manage SCS is to separate the clinical pathway from the payer transaction. Clinically, the pathway is staged: a screening trial establishes whether stimulation provides sufficient benefit, and permanent implantation follows only when the trial and the rest of the coverage criteria support proceeding. Medicare NCD 160.7 requires demonstration of pain relief with a temporary electrode before permanent implantation. ^S1

Gate 1 - candidacy and trial

Before trial, the record should establish the diagnosis and pain generator, chronicity and severity, prior treatment history, why other appropriate modalities failed or were unsuitable or contraindicated, multidisciplinary screening, psychological evaluation where required, and the planned trial procedure. These are evidence domains; the exact payer checklist must still be verified for the patient and plan.

Gate 2 - permanent implantation

Before permanent implantation, the program should add quantified trial-response documentation, functional change when required, medication change when relevant, complications, the planned permanent approach, site of service, rendering/operating provider, and the code set that accurately reflects the intended procedure.

GoHealthcare Recommendation: pre-stage the permanent-implant evidence packet as soon as the trial pathway is approved or scheduled. Do not submit a second request unless the payer/program actually requires one; instead, prepare the documentation so the correct next transaction can occur immediately when trial outcomes are available.

The Medicare coverage baseline: NCD 160.7

Classification: CMS National Coverage Determination / Medicare coverage policy. NCD 160.7 is the national Medicare coverage baseline for electrical nerve stimulators. For dorsal-column/spinal cord neurostimulation, Medicare may cover implantation for chronic intractable pain when the national conditions are satisfied. ^S1

The stimulator is used only as a late resort - if not a last resort - for chronic intractable pain.
Other treatment modalities, including pharmacological, surgical, physical, or psychological therapies, have been tried without satisfactory result, or are judged unsuitable or contraindicated for the patient.
The patient has undergone careful screening, evaluation, and diagnosis by a multidisciplinary team; the NCD expressly includes psychological as well as physical evaluation.
The facilities, equipment, professional personnel, and support personnel required for diagnosis, treatment, training, and follow-up are available.
Pain relief is demonstrated with a temporarily implanted electrode before permanent implantation.

Operational consequence: “failed conservative care” should not remain a conclusory phrase. A defensible file should identify the therapy, approximate dates or period, response, and why it was discontinued, unsuccessful, unsuitable, or contraindicated. That level of detail is a GoHealthcare documentation standard designed to make the NCD requirement visible and auditable; it is not a verbatim national CMS documentation template.

Audit consequence: Do not rely on historical denial percentages unless the underlying primary review report is cited and still relevant. What can be stated currently is that CMS has an approved RAC topic for spinal cord neurostimulation medical necessity and documentation requirements, including CPT 63685. That makes complete coverage documentation a continuing audit-control issue. ^S9

Original Medicare: the authorization pathway must be routed by setting and code

A major operational error is to ask only, “Does Medicare require prior authorization for SCS?” The correct routing question is: Which Original Medicare program applies to this beneficiary, code, setting, state, and date of service?

Scenario	Program	Operational rule
Hospital OPD + CPT 63650	Nationwide Hospital OPD PA program	Prior authorization is a condition of payment for the selected HOPD service. Implanted spinal neurostimulators entered this program July 1, 2021. Current code list includes 63650. ^{S2 S3 S4}
Same HOPD/physician: trial 63650 -> permanent 63650	Hospital OPD PA program	CMS says only the trial PAR is required; reuse the trial UTN on the permanent 63650 claim. ^S3
Trial outside HOPD -> permanent 63650 in HOPD	Hospital OPD PA program	A hospital OPD PAR is required for the permanent 63650 service. ^S3
CPT 63655 in AZ, NJ, OH, OK, TX, WA for Original Medicare	WISeR	Current WISeR SCS scope includes 63655 and applies PA or pre-payment review to permanent implantation. 63650 is excluded from WISeR because it is already covered by the HOPD PA program when applicable. ^S5
CPT 63685 / 63688 in HOPD	Current HOPD code list	These codes are currently temporarily removed from the HOPD services requiring PA. This does not eliminate medical-necessity, coding, or other payer requirements. ^S4
Medicare Advantage	MA plan process	Contact the MA plan for its PA workflow. Medical-necessity criteria remain constrained by Medicare coverage rules under 42 CFR 422.101. ^S8

Nationwide Hospital OPD prior authorization for CPT 63650

CMS established a nationwide PA process for selected Hospital OPD services, and implanted spinal neurostimulators became subject to that program for services provided on or after July 1, 2021. The current CMS code list identifies CPT 63650. ^{S2 S4}

Current operational timeframes: CMS states that standard initial and resubmitted HOPD prior-authorization decisions are issued within 7 calendar days of receipt. When the MAC validates that delay could jeopardize the beneficiary’s life or health, expedited review is targeted within 2 business days. HOPD PAR decisions and UTNs are valid for 120 days. ^{S2 S3}

For SCS trial or permanent placement under the HOPD program, CMS guidance calls for documentation of the condition, physical examination, treatments tried and failed, and an appropriate psychological evaluation. For permanent placement, the record must also document pain relief from the temporary electrode. CMS’s HOPD guide describes a successful trial as at least 50% reduction of target pain or 50% reduction of analgesic medication. Applicable MAC coverage rules may add or further interpret requirements. ^S3

Claim control: When a service requires HOPD PA as a condition of payment, a claim submitted without the required PA determination and corresponding UTN is automatically denied. CMS also states that related OPD services may be denied when the primary PA-required service is not paid. ^S3

WISeR: a separate Original Medicare model in six states

Classification: CMS Innovation Center model and operational guidance. WISeR began in 2026 in Arizona, New Jersey, Ohio, Oklahoma, Texas, and Washington and is scheduled to run through December 31, 2031. It applies to selected Original Medicare items and services, not Medicare Advantage. ^S5

WISeR does not change Medicare coverage criteria. It changes the review architecture. A provider furnishing a selected WISeR service may submit a prior-authorization request before service or proceed without PA and have the claim routed to pre-payment medical review. Avoiding the PAR therefore does not avoid medical review; it moves the determination after the service. ^S5

For SCS, the current Version 7.0 guide is specific: WISeR initially focuses on permanent implantation and does not include CPT 63650. Appendix A identifies CPT 63655. The required-documentation section calls for the condition and exam, late-resort treatment history, multidisciplinary evaluation, demonstrated pain reduction and functional improvement during the temporary trial, and documentation explaining why percutaneous leads are not appropriate for the 63655 case. ^S5

Current WISeR review timeframes are typically 3 calendar days for standard PA determinations and 2 calendar days for an expedited request when the serious-jeopardy standard is met. An affirmed WISeR PA/UTN is generally valid for 120 calendar days. ^S5

UTN control under WISeR is setting-specific. For Hospital OPD and ASC services, CMS directs that the UTN be submitted with the facility-based claim; the model selects facility-based encounters rather than professional services in those settings. Associated items and services - including anesthesia, devices, physician services, and facility services - do not undergo separate WISeR prior authorization, but payment can follow the primary service outcome. ^S5

WISeR exemption: active beginning July 2026

The exemption program should no longer be described as merely forthcoming. The July 24, 2026 WISeR guide states that CMS and WISeR participants implemented an exemption process beginning in July 2026. Exemption is granted at the individual provider NPI level, not the organization or facility level. ^S5

Baseline qualification requires at least 10 prior-authorization requests across WISeR selected items and services during an exemption assessment period.
The provider must meet a minimum affirmation-rate threshold; participants have flexibility in program design and may publish additional participant-specific criteria.
Qualifying providers are added to exemption status on a quarterly basis.
Exemption status is maintained for at least one year, subject to the participant’s rules and reevaluation using additional documentation requests.

Operational implication: manage WISeR affirmation quality by NPI and across all WISeR services, not only SCS. An SCS-specific approval rate is useful for service-line management but does not by itself determine exemption eligibility.

MAC local coverage policy: national baseline, local detail

NCD 160.7 provides the national Medicare coverage conditions. Where an applicable MAC LCD or billing/coding article exists, it may provide additional local coverage, utilization, documentation, or coding detail consistent with the national policy. Multi-state organizations should therefore maintain a jurisdiction map instead of copying one MAC’s limits into an enterprise-wide Medicare rule.

Example only - not a national limit: current Medicare article A56876 includes contractor-specific utilization parameters for temporary trials and permanent paddle implantation and directs users to the NCCI for code combinations. Those limits belong in a payer/MAC matrix with the jurisdiction and effective version attached. ^S7

A current Noridian SCS LCD also states that when an existing stimulator has been working well and needs replacement because of battery change, malfunction, or end of service life, a new trial is not required. That distinction is important: the need for a new clinical trial is not the same question as whether a payer requires a new authorization transaction for a replacement. ^S6

Medicare Advantage is not simply “commercial Medicare”

Medicare Advantage should be operationally separated from commercial coverage. MA plans may impose prior-authorization processes, but federal rules govern how medical necessity is determined for Medicare basic benefits. Under 42 CFR 422.101, MA organizations may use publicly accessible internal coverage criteria when applicable Medicare statutes, regulations, NCDs, or LCDs do not fully establish the criteria; they may not use internal criteria as a blanket replacement for established Medicare coverage standards. ^S8

Operational rule: for an MA SCS case, confirm both the plan’s current authorization workflow and the Medicare coverage policy hierarchy applicable to that member. Staff should not assume that a commercial policy from the same parent company is automatically the correct MA medical-necessity standard.

Commercial payer criteria: more variable and often more granular

Commercial medical policies vary by payer, product, employer plan, state, diagnosis, technology, and date of service. Representative policies show that commercial payers may require substantially more granular documentation than the national Medicare NCD. Aetna CPB 0194, for example, contains detailed SCS candidacy and trial criteria. That is evidence of payer variability, not a universal commercial rule. ^S10

Common evidence domains to validate against the specific plan include:

Duration and severity of pain and the covered diagnosis/indication.
A structured record of conservative and interventional treatment attempts, including response or contraindication.
Whether further corrective surgery is indicated or has been addressed, when required by policy.
Behavioral-health or psychological assessment requirements, including who may perform the evaluation and how recent it must be.
Trial duration and the payer’s definition of a successful trial, including pain, function, medication use, and complications where required.
Technology-specific limitations or separate criteria for a particular stimulation modality or indication.
Device, site-of-service, network, rendering-provider, and facility authorization requirements.

Where preventable SCS denials originate

There is no current national dataset in the sources reviewed that supports naming one universal “most common” SCS denial reason. A more defensible operating statement is that preventable denials frequently arise when the evidence file or transaction does not match the applicable policy. The following taxonomy should be used as a root-cause framework, not as a national ranking.

Vulnerability	What the reviewer/claim sees	Operational remedy
Conservative-care gap	Chart says “failed conservative care” without a usable chronology	Build a dated treatment ledger with modality, duration, response, and contraindication/unsuitability where applicable.
Behavioral-health gap	Evaluation missing, outside payer window, performed by an unacceptable provider type, or lacking required content	Map evaluator type, timing, instruments/content, and clearance/risk statement to the specific payer.
Trial-result gap	Narrative says “good relief” but does not quantify the payer’s required success measure	Use a trial outcome form capturing baseline/post-trial pain, percentage change, function, medication change, complications, and duration.
Indication mismatch	Diagnosis submitted does not match covered indication or documented pain generator	Validate diagnosis/indication against the current policy before submission.
Transaction mismatch	Authorization, date range, provider, facility, code, units, or claim differ	Reconcile authorization/UTN to scheduling and claim before service and again before billing.
Wrong Medicare pathway	HOPD 63650, WISeR 63655, MA, or other FFS pathway routed incorrectly	Use a Medicare routing decision tree keyed to beneficiary type, CPT, setting, state, and MAC.

The GoHealthcare SCS Authorization Evidence File

Related case study: See how this framework translates into real-world SCS workflow performance in Accelerating Spinal Cord Stimulation Prior Authorizations.

Classification: GoHealthcare Analysis - proposed operating framework. The objective is a standardized evidence file that can support the appropriate stage of authorization, peer-to-peer review, appeal, scheduling, claim reconciliation, and audit response. The file should be built at candidacy determination and maintained rather than reconstructed under deadline pressure.

#	Evidence domain	Minimum operating content
1	Pain history and chronicity	Onset, duration, distribution, character, baseline/longitudinal pain measures
2	Diagnosis and pain generator	Specific diagnosis, relevant imaging/exam correlation, laterality/level where applicable
3	Conservative-care ledger	Dated modality-by-modality record, duration, response, reason discontinued/unsuitable/contraindicated
4	Interventional/surgical history	Prior injections, ablations, surgeries, dates, outcomes
5	Surgical candidacy / treatment-pathway statement	Why corrective surgery is or is not indicated when policy requires it
6	Behavioral-health evaluation	Evaluator credentials, date, required content/instruments, plan-specific acceptance criteria
7	Trial outcome record	Pre/post measures, percentage change, function, medication change, complications, trial duration
8	Procedure and site plan	Planned approach, relevant CPT family, site, facility, physician, technology, dates/units
9	Authorization and claim-integrity record	Payer/program, request ID/UTN, decision, approved codes/units/dates/site/provider, handoff and reconciliation evidence
10	Program capability / longitudinal follow-up	Device management, programming/follow-up capability, ongoing benefit documentation and device registry

Note: this ten-domain architecture is a GoHealthcare operating framework. It intentionally exceeds the wording of any one payer policy so that the same core evidence can be mapped to different payer rules without rebuilding the chart from scratch.

Coding and authorization alignment: authorize the service you actually intend to perform

SCS generates multiple code families and often multiple claims. Authorization staff do not need to function as coders, but they do need enough code literacy to detect a mismatch between the clinical plan and the authorization request.

Code family	Operational orientation	Authorization/coding control
63650	Percutaneous epidural lead placement; may be used in trial or permanent percutaneous workflows	Current Hospital OPD PA code under Original Medicare when furnished in that setting. Verify units, payer criteria, and claim rules.
63655	Laminectomy/paddle lead implantation	Current WISeR SCS selected code in the six WISeR states for applicable Original Medicare cases.
63661-63664	Lead removal/revision family	Verify current CPT/NCCI, site-of-service, and payer authorization requirements.
63685 / 63688	Generator insertion/replacement and revision/removal family	Currently temporarily removed from the nationwide Hospital OPD PA code list, but other payer/coverage requirements may still apply.
95970-95972	Programming/analysis family	Use current CPT/NCCI and payer billing policy; do not assume separate payment in every procedural context.

CPT/HCPCS copyright and coding note: code numbers are referenced only to orient the authorization workflow. Current CPT descriptors, NCCI edits, units, modifiers, bundled services, and payer-specific coding instructions must be verified for the date of service.

Do not request speculative “contingency codes” as a universal practice. Submit the code set that accurately reflects the planned service. If the payer’s process permits documentation of a foreseeable intraoperative alternative, clarify it before the date of service; if the clinical plan materially changes, obtain an amended or new authorization when required.

Device coding and site-of-service payment: keep the guide principle-based

Device reporting and reimbursement vary across Medicare payment systems and non-Medicare contracts. Hospital OPPS, ASC, physician-office, and commercial billing rules should not be collapsed into one evergreen device-code statement. The operating control is to validate the applicable payment system, current CMS code editor/payment files, payer contract, and claim format for the date of service before assuming whether a device is separately reportable or separately payable.

GoHealthcare Recommendation: maintain a site-of-service coding matrix outside the evergreen article and version it by calendar year. That matrix can contain the current device HCPCS/C-codes, packaging status, claim form, revenue-code requirements, and payer-specific instructions without creating stale statements in the core authority asset.

The multi-claim problem: authorization integrity must cross organizational boundaries

An SCS procedure may generate facility, professional, anesthesia, device-related, and follow-up claims. The authorization process therefore has to identify which entity owns the primary authorization, which service is actually subject to PA, which associated claims depend on the primary determination, and where any UTN or authorization identifier must appear.

Under the Hospital OPD PA program, the PA-required HOPD claim must carry the corresponding UTN, and related OPD services may be affected when the primary service is not paid. Under WISeR, CMS states that HOPD and ASC review is facility-based; the UTN is submitted on the facility-based claim, while associated services do not undergo separate WISeR PA but can be denied if the primary service is non-affirmed or denied. ^{S3 S5}

Revisions, replacements, and explants: do not assume either “always PA” or “never PA”

Downstream SCS procedures require a fresh payer check because authorization rules differ by service, setting, plan, and date. The current CMS Hospital OPD code list temporarily removes CPT 63685 and 63688 from the services requiring HOPD PA. That means a blanket statement that every generator replacement requires a new Original Medicare HOPD prior authorization is incorrect. ^S4

Medical necessity and documentation still matter. For example, a current Noridian LCD states that a new SCS trial is not required when a previously effective device needs replacement for battery change, malfunction, or end of life. Other Medicare jurisdictions, Medicare Advantage plans, and commercial payers must be checked separately. ^S6

GoHealthcare Recommendation: maintain longitudinal benefit documentation from implantation forward. Capture pain/function, medication use where relevant, device utilization, programming issues, complications, implant date/system, and anticipated service-life milestones. This improves replacement readiness without inventing a universal authorization rule.

Workers' compensation, no-fault, and PIP: separate authorization architecture

Workers’ compensation, automobile no-fault, and PIP cases should not be routed through a commercial-health-plan SCS workflow by default. Authorization, causation, treatment guidelines, utilization review, appeal rights, fee schedules, and deadlines are jurisdiction-specific. The Medicare NCD is not the governing utilization-review rule for a state workers’ compensation or PIP authorization decision, although Medicare Secondary Payer obligations may still apply when the patient is a Medicare beneficiary.

GoHealthcare Recommendation: create separate state-specific pathways with a current legal/regulatory source, carrier/UR requirements, causation evidence, filing calendar, and appeal route. New Jersey should be treated as a distinct operating competency for organizations with meaningful PIP/no-fault volume.

The SCS Authorization Scorecard: what leadership should measure

Classification: GoHealthcare Analysis - proposed KPI framework. Approval alone is a lagging measure. The program should track leading evidence quality, transaction integrity, access time, downstream conversion, and audit exposure.

#	Metric	Definition	Why it matters
1	Trial first-pass approval/affirmation rate	Approved/affirmed initial trial requests ÷ initial trial requests	Measures candidacy-file quality for payers/programs where a trial PA is required.
2	Permanent first-pass approval/affirmation rate	Approved/affirmed initial permanent requests ÷ initial permanent requests	Measures trial-outcome and permanent-plan documentation quality where a separate request is required.
3	Referral-to-trial decision cycle time	Calendar days from candidacy determination to payer decision/clearance	Patient-access and scheduling indicator.
4	Trial-to-permanent interval	Calendar days from trial completion to permanent service	Shows whether Gate 2 documentation and payer routing were pre-staged.
5	Evidence-file completeness at submission	% of cases meeting all required GoHealthcare evidence domains and payer-mapped fields	Actionable leading indicator before payer review.
6	Behavioral-health policy compliance	% with payer-conforming evaluation in-window at submission	Targets a recurring high-risk documentation domain.
7	P2P conversion rate	Approvals after peer-to-peer ÷ peer-to-peer cases	Helps distinguish documentation/remediable issues from policy disputes.
8	Appeal overturn rate by root cause	Overturns ÷ appeals, segmented by denial reason	Identifies upstream process failures and appeal-worthy policy disputes.
9	Authorization-to-claim match rate	% with code/units/site/date/provider/identifier reconciled before billing	Prevents transaction defects.
10	Post-payment evidence-gap exposure	Count and estimated allowed/paid dollars for implanted cases with known evidence gaps	Sizes retrospective documentation risk.
11	WISeR exemption readiness by NPI	PAR count and affirmation performance across WISeR selected services by individual NPI	Tracks the baseline inputs CMS identifies for WISeR exemption; participant-specific criteria still apply.

Metric 5 is one of the most actionable leading indicators because it can be measured before submission. Metric 11 must be managed at the individual NPI level and across WISeR selected services; an SCS-only rate is not equivalent to WISeR exemption qualification. ^S5

An SCS authorization maturity model

Level 1 - Reactive

Cases are worked individually; payer criteria live in staff memory; no evidence-file standard; weak visibility into aging, denials, or audit gaps.

Level 2 - Standardized

Checklist and templates exist; top payer criteria are documented; ownership is named; approval/denial rates are tracked.

Level 3 - Engineered

Evidence file is built at candidacy; payer/program routing is explicit; Gate 2 is pre-staged; authorization-to-claim reconciliation is a standing control; WC/PIP is separate.

Level 4 - Intelligence-driven

Structured data captures root cause, reviewer requests, turnaround, appeal/P2P outcomes, authorization/claim mismatch, and NPI-level WISeR exemption readiness; policy versions are governed and used to predict intervention needs.

Diagnostic question: Can leadership produce, without manually opening charts, a current list of every active and recently implanted SCS case showing payer/program pathway, evidence completeness, authorization/UTN status, approved code/site/provider/date, trial outcome, claim reconciliation, and known audit gaps? If not, the program has not yet reached an engineered state.

The executive economics: why this is a margin and capacity conversation

SCS authorization affects more than denial rate. A preventable authorization or documentation failure can expose device-intensive facility resources, professional and anesthesia revenue, rescheduling costs, and operating-room capacity. Avoidable delay can leave high-value blocks underutilized. Trial-to-permanent abandonment is also invisible in a conventional denial report because the case may disappear before a claim is ever submitted.

The audit risk is systemic when the same documentation habit is repeated across cases. The appropriate executive response is therefore not simply a stronger appeals team. It is a controlled evidence architecture, correct payer-program routing, authorization-to-claim reconciliation, and measurable remediation of known gaps.

A 90-day build plan for a defensible SCS authorization program

Days 1-30 - establish the baseline

Inventory SCS volume by payer, plan/product, state, site of service, CPT family, physician/NPI, and facility.
Build the Original Medicare routing map: HOPD 63650; WISeR 63655 in the six model states; current MAC LCD/LCA by jurisdiction; other FFS pathways as applicable.
Separate Medicare Advantage from commercial policy mapping and attach the current plan policy/effective date to each rule set.
Audit a sample of recent trial, permanent, replacement, revision, and explant cases against the evidence-file domains and transaction match.
Identify any use of retired or superseded policies in staff references and remove them from the active library.

Days 31-60 - engineer the workflow

Implement the evidence-file template in the EHR/authorization platform with hard stops for payer-required fields.
Build a payer criteria matrix that stores source, effective date, version, jurisdiction, covered indications, behavioral-health requirements, trial-success definition, site, codes/units, and PA transaction rules.
Pre-stage permanent evidence during the trial without assuming that a separate PA submission will be required.
Define a documented handoff between authorization, scheduling, facility, physician billing, and anesthesia/device stakeholders.
Create separate workers’ compensation, no-fault, and PIP workflows with jurisdiction-specific calendars.

Days 61-90 - instrument and govern

Launch the SCS scorecard with written metric definitions and monthly executive ownership.
Track denial reasons, reviewer requests, peer-to-peer outcomes, and appeal outcomes at a structured root-cause level.
Implement pre-service and pre-bill authorization-to-claim reconciliation.
Track WISeR exemption-readiness inputs by individual NPI across WISeR selected services where applicable.
Create the implanted-device registry and longitudinal benefit-documentation standard.
Schedule a policy-refresh control for CMS HOPD code lists, WISeR guide/appendices, MAC policies, MA policies, and top commercial payers.

Frequently asked questions about spinal cord stimulator authorization

Does Original Medicare require prior authorization for SCS?

In specific circumstances, yes. CMS has required prior authorization for implanted spinal neurostimulators in the nationwide Hospital OPD program since July 1, 2021; the current list includes CPT 63650. Separately, WISeR applies to CPT 63655 for applicable Original Medicare cases in Arizona, New Jersey, Ohio, Oklahoma, Texas, and Washington, using PA or pre-payment review. Other Original Medicare SCS services/settings must be routed under current CMS/MAC rules. Medicare Advantage uses the plan’s PA process. ^{S2 S3 S4 S5}

Are the SCS trial and permanent implant always authorized separately?

No. They are separate clinical stages, but not universally separate PA transactions. CMS HOPD guidance allows one trial PAR/UTN to support the permanent 63650 claim when both are performed by the same physician at the same hospital OPD. Commercial and MA plans may require separate trial and permanent requests. ^S3

What is the most common reason SCS is denied?

A current national source reviewed for this edition does not support a universal ranking. Recurring preventable vulnerabilities include incomplete treatment chronology, non-conforming behavioral-health evaluation, unquantified trial outcomes, indication mismatch, and authorization/claim mismatch. CMS RAC topic 0207 confirms active medical-necessity/documentation review of SCS. ^S9

How much improvement does an SCS trial need to show?

It depends on the applicable policy. CMS HOPD guidance describes a successful trial as at least 50% reduction of target pain or 50% reduction of analgesic medication. Some MAC or payer policies also expect functional improvement. Commercial thresholds and measures vary. ^{S3 S6 S10}

What is a UTN and where does it go?

A Unique Tracking Number is generated for CMS prior-authorization transactions such as the HOPD PA program and WISeR. It must be placed on the claim for the prior-authorized service according to the program’s claim instructions. Under WISeR, HOPD/ASC review is facility-based and CMS directs the UTN to the facility-based claim; associated services do not undergo separate WISeR PA. ^{S3 S5}

Can a provider skip WISeR prior authorization?

Yes, because the PAR is voluntary within WISeR. But the claim for a selected WISeR service without a PA decision is routed to pre-payment medical review, so the provider has not avoided coverage review. ^S5

Do generator replacements require a new prior authorization?

There is no universal answer. The current CMS Hospital OPD PA list temporarily removes CPT 63685 and 63688, while MA and commercial plans may require authorization. Coverage and documentation still apply. A current Noridian LCD also states that a new trial is not required for routine replacement of a previously effective stimulator because of battery change, malfunction, or end of life. ^{S4 S6}

What is WISeR exemption and does SCS performance matter?

Beginning in July 2026, CMS and WISeR participants implemented an exemption process at the individual NPI level. Baseline eligibility includes at least 10 PARs across WISeR selected services during the assessment period plus a minimum affirmation threshold set within the participant program. SCS performance can contribute, but SCS alone is not the entire exemption calculation. ^S5

How should workers’ compensation and PIP SCS cases be handled?

Use the applicable state statute, treatment guideline, utilization-review process, carrier rule, and appeal deadline. Do not automatically apply a commercial-health-plan or Medicare authorization template. For Medicare beneficiaries, also evaluate Medicare Secondary Payer requirements as appropriate.

What leadership should take from this

SCS authorization rewards programs that treat evidence and transaction integrity as infrastructure. The clinical coverage baseline under Medicare NCD 160.7 is longstanding. What has evolved is the authorization and review architecture: a nationwide Hospital OPD PA pathway for implanted spinal neurostimulators has existed since 2021, and WISeR added a distinct 2026 technology-enhanced PA/pre-payment-review pathway for selected services - including CPT 63655 - in six states. ^{S1 S2 S3 S4 S5}

The operating advantage comes from getting the routing and evidence right before submission: the correct payer policy, current effective version, complete evidence file, correct code/site/provider/date, quantified trial outcome, correct UTN handling, and reconciliation to the final claim. Appeals remain necessary, but the highest-value program is the one that prevents avoidable non-affirmations and denials upstream.

Primary sources validated for this edition

Validation date: August 19, 2026. Re-check payer policies, CMS program guides, code lists, LCDs/LCAs, and coding edits for the patient, date of service, and jurisdiction before operational reliance.

Update-sensitive notes

CMS HOPD code lists, WISeR selected services, participant-specific exemption criteria, review procedures, MAC LCDs/LCAs, CPT/NCCI rules, Medicare Advantage policies, commercial policies, state workers’ compensation/no-fault rules, and payment-system instructions can change. Re-verify them for the patient, plan, jurisdiction, procedure, setting, and date of service before operational reliance.

Disclaimer

This publication is educational and operational in nature. It is not legal, compliance, coding, reimbursement, or medical advice and does not replace the current applicable payer policy, statute, regulation, CMS coverage determination, CMS operational guide, MAC policy, state rule, or patient-specific clinical judgment. Prior authorization or provisional affirmation is not a guarantee of payment; claims remain subject to applicable coverage, coding, payment, eligibility, benefit, and technical requirements.

About the author

Pinky Maniri, MSc is CEO and Founder of GoHealthcare Practice Solutions, a national specialty healthcare operations, technology, and intelligence company serving interventional pain, orthopedic spine, neurosurgery, PM&R, neuromodulation, and ambulatory surgery center organizations. Her work spans patient access, prior authorization, clinical documentation, coding and reimbursement operations, revenue integrity, compliance, and healthcare AI governance.